Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LYRA | Lyra Therapeutics, Inc.

Index- P/E- EPS (ttm)-1.59 Insider Own0.88% Shs Outstand43.68M Perf Week-5.76%
Market Cap238.59M Forward P/E- EPS next Y-1.27 Insider Trans- Shs Float36.35M Perf Month34.35%
Income-60.90M PEG- EPS next Q-0.32 Inst Own78.20% Short Float / Ratio0.15% / 0.15 Perf Quarter17.55%
Sales1.20M P/S198.83 EPS this Y45.40% Inst Trans-0.21% Short Interest0.06M Perf Half Y106.54%
Book/sh2.26 P/B1.96 EPS next Y14.80% ROA-54.20% Target Price12.50 Perf Year-25.96%
Cash/sh2.15 P/C2.05 EPS next 5Y-1.60% ROE-71.90% 52W Range1.86 - 6.11 Perf YTD40.76%
Dividend- P/FCF- EPS past 5Y- ROI-69.70% 52W High-27.66% Beta-0.22
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low137.63% ATR0.39
Employees73 Current Ratio8.40 Sales Q/Q-50.00% Oper. Margin- RSI (14)61.13 Volatility11.85% 9.67%
OptionableYes Debt/Eq0.00 EPS Q/Q55.90% Profit Margin- Rel Volume0.42 Prev Close4.80
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume362.14K Price4.42
Recom1.40 SMA2014.97% SMA5026.56% SMA20051.74% Volume151,485 Change-7.92%
Date Action Analyst Rating Change Price Target Change
Aug-31-23Initiated H.C. Wainwright Buy $12
May-24-22Initiated Cantor Fitzgerald Overweight $15
May-26-20Initiated William Blair Outperform
May-26-20Initiated Jefferies Buy $24
May-26-20Initiated BTIG Research Buy $28
May-26-20Initiated BofA/Merrill Buy $21
Sep-13-23 01:22PM
Sep-12-23 07:00AM
Sep-06-23 08:00AM
Aug-29-23 07:00AM
Aug-08-23 05:50PM
04:01PM Loading…
Jul-13-23 07:30AM
Jun-02-23 04:01PM
Jun-01-23 07:29AM
May-26-23 07:57AM
May-14-23 08:19AM
May-12-23 08:15AM
May-09-23 04:01PM
08:19AM Loading…
Apr-29-23 08:19AM
Apr-25-23 07:59AM
Mar-29-23 04:06PM
Mar-20-23 01:11PM
Mar-01-23 05:21AM
Feb-28-23 05:17AM
Feb-27-23 07:59AM
Feb-07-23 01:23PM
Feb-06-23 07:56AM
Jan-17-23 06:42PM
Dec-20-22 08:52AM
Nov-09-22 08:00AM
Nov-08-22 05:45PM
Sep-21-22 06:11AM
04:01PM Loading…
Sep-13-22 04:01PM
Sep-10-22 08:00AM
Sep-08-22 07:00AM
Sep-06-22 07:00AM
Aug-31-22 02:08PM
Aug-29-22 07:00AM
Aug-11-22 08:05AM
Aug-09-22 08:25AM
Jul-27-22 09:40AM
Jul-13-22 09:21AM
Jul-05-22 07:00AM
Jun-17-22 04:01PM
May-26-22 07:00AM
May-25-22 01:07PM
May-10-22 08:35AM
May-05-22 07:00AM
Apr-29-22 09:07AM
Apr-27-22 06:31AM
Apr-25-22 07:00AM
Apr-21-22 07:00AM
Apr-13-22 07:00AM
Apr-08-22 07:34AM
Mar-09-22 07:00AM
Mar-07-22 07:00AM
Mar-02-22 04:28AM
Feb-28-22 07:00AM
Feb-17-22 07:00AM
Jan-24-22 12:37PM
Nov-11-21 07:00AM
Nov-09-21 04:05PM
Nov-02-21 07:00AM
Oct-04-21 07:00AM
Sep-29-21 02:58PM
Sep-21-21 07:00AM
Sep-20-21 07:00AM
Sep-13-21 07:00AM
Sep-09-21 04:05PM
Sep-07-21 07:00AM
Sep-03-21 10:24AM
Aug-17-21 07:35AM
Aug-09-21 04:05PM
Aug-03-21 09:01AM
Jul-26-21 04:05PM
Jul-12-21 07:00AM
Jun-30-21 07:00AM
Jun-23-21 03:23PM
Jun-09-21 05:48AM
Jun-08-21 04:30PM
Jun-02-21 07:00AM
Jun-01-21 07:00AM
May-24-21 07:00AM
May-11-21 04:05PM
May-06-21 04:05PM
May-03-21 06:08AM
Apr-27-21 08:39AM
Mar-29-21 04:05PM
Mar-09-21 04:05PM
Mar-04-21 11:43AM
Mar-02-21 04:05PM
Mar-01-21 08:43AM
Feb-17-21 08:00AM
Feb-10-21 05:05PM
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLCDirectorMay 31Buy2.493,610,8328,999,99911,469,117Jun 02 04:11 PM
NBVM GP, LLC10% OwnerMay 31Buy2.431,805,4164,387,1612,521,745Jun 02 04:15 PM
ANDERSON EDWARD TDirectorMay 31Buy2.431,805,4164,387,1612,521,745Jun 02 04:11 PM